Ibnsina Pharma (ISPH) Stock Overview
Operates as a pharmaceutical distributor in Egypt. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 2/6 |
| Dividends | 1/6 |
ISPH Community Fair Values
Create NarrativeSee what 33 others think this stock is worth. Follow their fair value or set your own to get alerts.
Ibnsina Pharma Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ج.م10.60 |
| 52 Week High | ج.م13.72 |
| 52 Week Low | ج.م8.17 |
| Beta | 0.69 |
| 1 Month Change | 1.92% |
| 3 Month Change | -1.40% |
| 1 Year Change | 20.45% |
| 3 Year Change | 640.22% |
| 5 Year Change | 219.55% |
| Change since IPO | 144.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| ISPH | EG Healthcare | EG Market | |
|---|---|---|---|
| 7D | 1.5% | 3.4% | 3.5% |
| 1Y | 20.5% | 57.0% | 50.1% |
Return vs Industry: ISPH underperformed the EG Healthcare industry which returned 57% over the past year.
Return vs Market: ISPH underperformed the EG Market which returned 50.1% over the past year.
Price Volatility
| ISPH volatility | |
|---|---|
| ISPH Average Weekly Movement | 6.0% |
| Healthcare Industry Average Movement | 5.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in EG Market | 7.8% |
| 10% least volatile stocks in EG Market | 3.3% |
Stable Share Price: ISPH has not had significant price volatility in the past 3 months compared to the EG market.
Volatility Over Time: ISPH's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Mohamed Mohsen Mahgoub | ibnsina-pharma.com |
Ibnsina Pharma operates as a pharmaceutical distributor in Egypt. The company offers pharmaceutical and cosmetics products to private and public-sector customers, including retail chains, independent pharmacies, wholesalers, hospitals, and healthcare institutions. It also provides warehousing and logistics services for its suppliers; marketing solutions; importation and packaging services; and market research and analysis services, as well as telesales and promotion services.
Ibnsina Pharma Fundamentals Summary
| ISPH fundamental statistics | |
|---|---|
| Market cap | ج.م10.68b |
| Earnings (TTM) | ج.م771.11m |
| Revenue (TTM) | ج.م76.60b |
Is ISPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ISPH income statement (TTM) | |
|---|---|
| Revenue | ج.م76.60b |
| Cost of Revenue | ج.م70.15b |
| Gross Profit | ج.م6.45b |
| Other Expenses | ج.م5.68b |
| Earnings | ج.م771.11m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.76 |
| Gross Margin | 8.42% |
| Net Profit Margin | 1.01% |
| Debt/Equity Ratio | 920.4% |
How did ISPH perform over the long term?
See historical performance and comparisonDividends
Does ISPH pay a reliable dividends?
See ISPH dividend history and benchmarks| Ibnsina Pharma dividend dates | |
|---|---|
| Ex Dividend Date | Apr 27 2026 |
| Dividend Pay Date | Apr 29 2026 |
| Days until Ex dividend | 7 days |
| Days until Dividend pay date | 9 days |
Does ISPH pay a reliable dividends?
See ISPH dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/19 09:43 |
| End of Day Share Price | 2026/04/16 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ibnsina Pharma is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Marina Mikhail | CI Capital Research |
| Ahmed Moataz | EFG-Hermes Research |
| Marina Makeen | Pharos Research |